Tesofensine is a presynaptic monoamine reuptake inhibitor that simultaneously blocks the reuptake of dopamine, serotonin, and norepinephrine — three key neurotransmitters involved in appetite regulation, energy expenditure, and metabolic rate. Originally investigated for Alzheimer’s and Parkinson’s disease research, tesofensine attracted significant scientific interest after Phase 2 clinical trials revealed substantial effects on body weight and appetite regulation in metabolic research settings.
Unlike GLP-1 based compounds (semaglutide, tirzepatide, retatrutide), tesofensine works through an entirely different mechanism — targeting central nervous system monoamine pathways rather than peripheral gut hormone receptors. This makes it a distinct and complementary research tool for studying appetite and metabolic regulation.
Phase 2 clinical trial data published in The Lancet (2008) established tesofensine’s research profile:
Tesofensine’s triple mechanism differentiates it from single-target compounds:
By blocking dopamine transporter (DAT), tesofensine increases dopamine availability in reward circuits. This reduces the hedonic drive to eat — specifically targeting “eating for pleasure” rather than hunger-driven eating.
Blocking serotonin reuptake (SERT) increases central serotonin, which is a key satiety signal. Higher serotonin levels reduce meal size and promote earlier satiation.
Norepinephrine inhibition increases sympathetic nervous system activity, elevating resting metabolic rate and thermogenesis — meaning the body burns more calories at rest.
| Compound | Mechanism | Primary Research Focus | Status (2026) |
|---|---|---|---|
| Tesofensine | Triple monoamine reuptake inhibitor | CNS appetite, metabolic rate | Research compound |
| Semaglutide | GLP-1 receptor agonist | Peripheral appetite, insulin | FDA Approved |
| Tirzepatide | GLP-1 + GIP agonist | Peripheral appetite + insulin | FDA Approved |
| Retatrutide | GLP-1 + GIP + glucagon agonist | Peripheral + thermogenic | Phase 3 Trials |
Side effects observed in Phase 2 research were dose-dependent and primarily CNS-related:
The 0.5mg dose demonstrated the best tolerability profile while maintaining meaningful research effects. Most side effects were transient and resolved with continued administration.
Search data shows tesofensine growing from approximately 12,000 monthly searches in 2024 to over 20,000 in 2026 — a steady upward trend reflecting growing research community interest. At KD 12, it represents a relatively accessible keyword for research-focused content. The compound is sold for research use at Peptides For Sale in 30-tablet format.
Tesofensine is available as a research compound from licensed peptide suppliers. Key criteria when sourcing:
Peptides For Sale stocks Tesofensine 30 tablets (250mcg and 500mcg variants) with full CoA documentation. For laboratory and research use only.
Tesofensine is not FDA-approved for any indication. All information in this article is for educational and research reference purposes only. This is not medical advice. For laboratory and research use only — not intended for human consumption.
